Tags

Type your tag names separated by a space and hit enter

Ropinirole in the symptomatic treatment of Parkinson's disease.
J Neural Transm Suppl. 1995; 45:231-8.JN

Abstract

Ropinirole is a novel, non-ergoline dopamine agonist chemical name with a very high specificity for dopamine D2-like receptors, currently being investigated for the symptomatic treatment of Parkinson's disease. The efficacy of ropinirole has been investigated in three placebo-controlled studies: one using ropinirole as monotherapy in early Parkinson's disease and two using it as an adjunct to L-dopa in patients who are experiencing fluctuations in motor response. Ropinirole therapy for 12 weeks was an effective symptomatic therapy in both patient groups, as measured by either a significant improvement in the motor score of the UPDRS, reduction of awake time spent "off" or a reduction in the dose of L-dopa. Ropinirole therapy was generally well tolerated, the most frequent adverse events being nausea and vomiting which are typical of all dopamine agonists, but unlike other dopamine agonists, CNS side-effects were of the same magnitude as found patients receiving placebo.

Authors+Show Affiliations

MRC Cyclotron Unit. Hammersmith Hospital, London, United Kingdom.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

8748630

Citation

Brooks, D J., et al. "Ropinirole in the Symptomatic Treatment of Parkinson's Disease." Journal of Neural Transmission. Supplementum, vol. 45, 1995, pp. 231-8.
Brooks DJ, Torjanski N, Burn DJ. Ropinirole in the symptomatic treatment of Parkinson's disease. J Neural Transm Suppl. 1995;45:231-8.
Brooks, D. J., Torjanski, N., & Burn, D. J. (1995). Ropinirole in the symptomatic treatment of Parkinson's disease. Journal of Neural Transmission. Supplementum, 45, 231-8.
Brooks DJ, Torjanski N, Burn DJ. Ropinirole in the Symptomatic Treatment of Parkinson's Disease. J Neural Transm Suppl. 1995;45:231-8. PubMed PMID: 8748630.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ropinirole in the symptomatic treatment of Parkinson's disease. AU - Brooks,D J, AU - Torjanski,N, AU - Burn,D J, PY - 1995/1/1/pubmed PY - 1995/1/1/medline PY - 1995/1/1/entrez SP - 231 EP - 8 JF - Journal of neural transmission. Supplementum JO - J Neural Transm Suppl VL - 45 N2 - Ropinirole is a novel, non-ergoline dopamine agonist chemical name with a very high specificity for dopamine D2-like receptors, currently being investigated for the symptomatic treatment of Parkinson's disease. The efficacy of ropinirole has been investigated in three placebo-controlled studies: one using ropinirole as monotherapy in early Parkinson's disease and two using it as an adjunct to L-dopa in patients who are experiencing fluctuations in motor response. Ropinirole therapy for 12 weeks was an effective symptomatic therapy in both patient groups, as measured by either a significant improvement in the motor score of the UPDRS, reduction of awake time spent "off" or a reduction in the dose of L-dopa. Ropinirole therapy was generally well tolerated, the most frequent adverse events being nausea and vomiting which are typical of all dopamine agonists, but unlike other dopamine agonists, CNS side-effects were of the same magnitude as found patients receiving placebo. SN - 0303-6995 UR - https://www.unboundmedicine.com/medline/citation/8748630/Ropinirole_in_the_symptomatic_treatment_of_Parkinson's_disease_ DB - PRIME DP - Unbound Medicine ER -